Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2024-04-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
关于2024年度向银行申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the company's plan to apply for credit facilities from banks for the year 2024. It details the intended credit limits, types of credit products, and banks involved. There is no financial statement, audit information, or detailed financial analysis present. The document is a formal disclosure about financing activities, specifically about credit/loan applications and limits. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2024-04-26 Chinese
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "重庆博腾制药科技股份有限公司 2023 年年度报告摘要" which translates to "Chongqing Porton Pharmaceutical Technology Co., Ltd. 2023 Annual Report Summary." It contains detailed financial data for the year 2023, including total assets, net profit, revenue, and quarterly financial data. It also discusses business operations, industry context, strategic developments, R&D investments, and ESG initiatives. The document is comprehensive and covers the company's full financial performance and business overview for the fiscal year 2023. It is not a brief announcement or a presentation but a detailed annual report summary. Therefore, it fits the definition of an Annual Report (10-K).
2024-04-26 Chinese
2023年度利润分配预案
Notice of Dividend Amount Classification · 95% confidence The document is titled as a 2023 annual profit distribution plan from Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details the company's net profit, retained earnings, and proposed cash dividend distribution per share. The document mentions that the plan needs to be submitted to the 2023 annual shareholders' meeting for approval. The content focuses on dividend distribution amounts and related financial figures, which aligns with a Notice of Dividend Amount filing. The document length is short (893 characters), but it contains substantive dividend distribution details rather than just announcing a report publication or referencing a report. Therefore, it fits best under the Notice of Dividend Amount (DIV) category.
2024-04-26 Chinese
对外投资管理制度（2024年4月）
Governance Information Classification · 95% confidence The document is titled "对外投资管理制度" which translates to "External Investment Management System" and is issued by 重庆博腾制药科技股份有限公司 (Chongqing Boteng Pharmaceutical Technology Co., Ltd.). It is a detailed internal policy document outlining the company's procedures, principles, approval authorities, organizational management, decision-making processes, financial management, auditing, and disclosure obligations related to external investments. The document references relevant laws and regulations but does not contain financial statements, earnings data, or audit opinions. It is not an announcement or a report of financial results, nor is it a regulatory filing or a certification. It is a governance-related document detailing internal rules and procedures for managing external investments. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7701 characters) supports it being a substantive policy document rather than a brief announcement.
2024-04-26 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details the approval of various reports and proposals including the 2023 internal control self-evaluation report, 2023 financial settlement report, 2024 financial budget report, 2023 fundraising usage report, asset impairment provisions, foreign exchange derivative transactions, 2023 profit distribution plan, 2023 annual report and summary, 2024 Q1 report, stock incentive plan cancellations, and the 2023 Supervisory Board work report. The document references that the detailed reports are published separately on the CNINFO website and that these resolutions will be submitted to the 2023 annual shareholders meeting for approval. The document itself is a meeting resolution announcement and does not contain the full reports or substantive financial data. It is also under 5,000 characters. Therefore, it is not the reports themselves but an announcement of meeting resolutions and approvals. This fits best with the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-04-26 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the "2023年度财务决算报告" which translates to "2023 Annual Financial Settlement Report". It contains detailed audited financial statements for the full fiscal year 2023, including balance sheets, income statements, cash flow statements, and financial analysis. The audit opinion is mentioned with a standard unqualified opinion from an accounting firm. The document includes comprehensive financial data and analysis for the entire year, not just a summary or announcement. The length of the document (9894 characters) and the detailed financial content confirm it is the full annual report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K).
2024-04-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.